×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: A Multicenter, Phase III, Randomized, Double Blind, Placebo-
clinical
2,564 words
KG: A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study ... (NCT05143528)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
Contents
A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study ... (NCT05143528)
Knowledge Graph
Related Hypotheses (30)
Purinergic Signaling Polarization Control
Score: 0.55
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
TFEB-Independent Autophagy Bypass
Score: 0.51
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
APOE-Dependent Autophagy Restoration
Score: 0.61
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Noradrenergic-Tau Propagation Blockade
Score: 0.51
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Lysosomal Membrane Repair Enhancement
Score: 0.45
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.45
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
Show 25 more
Related Analyses (6)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 1 more
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Epigenetic Regulation Dysfunction in Alzheimer's and Parkins
clinical · proposed · Score: 0.40
See Also (15)
Section 204: Advanced Proteostasis and Protein Quality
therapeutic · Pages share 5 hypotheses
Section 201: Advanced Mitochondrial Biogenesis and PGC-
therapeutic · Pages share 5 hypotheses
Mitochondrial Replacement Therapy for Neurodegeneration
therapeutic · Pages share 5 hypotheses
Mitochondrial Biogenesis Inducers in Neurodegeneration
therapeutic · Pages share 5 hypotheses
Neurodegeneration
disease · Pages share 5 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 5 hypotheses
A Phase IIB, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 5 hypotheses
Optogenetically-Modified Neurons in Neurodegeneration R
cell · Pages share 5 hypotheses
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 4 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (2 edges)
A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study ... (NCT05143528)
references
ULK1
A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study ... (NCT05143528)
references
HDAC